(UroToday.com) In this session, Dr. Karim Fizazi reviewed evidence for “triplet therapy” comprising ADT plus radiation (RT) to the primary plus additional systemic therapy in metastatic hormone sensitive prostate cancer (mHSPC). He began by reviewing the evidence for each of these therapies individually in mHSPC, noting that systemic therapy should be intensified for most men with mHSPC. Meta-analysis of four trials demonstrated a 23% reduction in mortality for men with mHSPC with the addition of docetaxel to ADT. Likewise, the LATITUDE and STAMPEDE trials demonstrated significant improvement in overall survival (OS) in this setting.